Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joshua Meeks MD, PhD

Joshua J. Meeks MD, PhD

Assistant Professor of Urology and Biochemistry, and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Joshua Meeks is a urologic oncologist at Northwestern University and focuses on bladder cancer. His research group is funded by the VHA, Department of Defense and NCI.

Disclosures

Dr. Meeks reports the following:
  • Consultant: Merck, AstraZeneca, Ferring, Janssen, BMS, Foundation Medicine
  • Research Funding: Abbvie, Tesaro, Epizyme, Prostate Cancer Foundation, Hope Foundation, VHA, NIH, DoD
  • Compensation for talks/educational courses: AUA, OncLive, Olympus, UroToday
  • Clinical Trials: SWOG, Genentech, Merck, AstraZeneca, Incyte
  • 2 patents: T1 and TCGA classifier

Recent Contributions to PracticeUpdate:

  1. Detrimental Effect of Antibiotic Therapy in Patients With MIBC Receiving Neoadjuvant Pembrolizumab

Recently Updated